Telemedical, Intersectoral Network as New Digital Health Structure to Measurably Improve the Local Health Care

Infection Clinical Trial

— TELnet@NRW  

Official title:

Telemedical, Intersectoral Network as New Digital Health Structure to Measurably Improve the Local Health Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03137589
• Other study ID #: 16-162
• Status: Completed
• Phase: N/A
• Start date: May 1, 2017
• Est. completion date: January 31, 2020

Study information

• Verified date: January 2020
• Source: RWTH Aachen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Telemedicine allows providing expert know-ledge from specialized health centers to regional hospitals and practices. In this multicenter, prospective, non-interventional study hospitals and practices in NRW are supplied via a telematics platform with expertise from the university hospitals RWTH Aachen and Münster. The communication occurs via highly encrypted audio/video conference systems and a certified data exchange platform "Fallakte+". In total 40.000 outpatient and stationary patients with infectious diseases or need for intensive care should be treated with telemedical support. The participating hospitals and practices are randomly distributed into four clusters. The clusters are supplied with telemedicine at different time points but all clusters start at the same time collecting data from patient cohorts of infectiology and intensive care (e.g. symptom, therapeutic progress and outcome). The collected data is later compared to data obtained in the same way from patients treated with telemedical support and evaluated regarding differences in the quality of treatment, therapeutic process and the satisfaction of the patients with telemedicine. The aim is to improve the treatment quality in regional hospitals and practices of patients with serious and complex diseases and bring forward the application of telemedicine.

Description:

In future time the number of old people will significantly increase in Germany because of the demographic change taking place. The health care of the large number of old people will probably lead to a lack of physicians and an inefficient health care system. One strategy to tackle the problem could be telemedicine. Telemedicine makes it possible to provide know-ledge from experts to local hospitals and practices which otherwise need to send patients with serious and complex diseases to specialized trans-regional health centers. In this multicenter, prospective, non-interventional study hospitals and practices in NRW are supplied via a telematics platform with expert know-ledge from the university hospitals RWTH Aachen and Münster. The communication occurs via highly encrypted audio/video conference systems and a certified data exchange platform "Fallakte+".

In total 40.000 outpatient and stationary patients should be treated with telemedical support. Registered doctors will be involved in already existing practice networks to evaluate the potential for transfer and to ensure the sharing of know-ledge beyond the borders of individual sectors. The aim of the study is to improve the treatment quality of regional hospitals and practices and to increase the efficiency of the care of relevant patient cohort in the field of infectiology and intensive care with the main focus sepsis as those patient groups especially often require professional expertise for a successful therapy.

In the beginning of the study participating hospitals and practices are randomly distributed into four clusters (cluster randomization). The different clusters all start with the control phase but enter into the intervention phase at different times (stepped-wedge design). During the control phase data of patients with infection and intensive care patients routinely treated without the support of telemedicine are documented and the patients are asked to complete a questionnaire regarding health-related quality of life (SF36) directly after treatment and at two time points in the follow-up. The collected data will be later compared to data obtained in the same way from patients treated with telemedical support and evaluated regarding differences in the quality of treatment, therapeutic process and the satisfaction of the patients with telemedicine.

If the study shows that the treatment quality and therapeutic process of patients with infectious diseases or need for intensive care is improved by telemedicine, the telematics platform can be expanded and used by other specialized fields and users in future time.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 159065
• Est. completion date: January 31, 2020
• Est. primary completion date: October 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• majority

• written informed consent

• infectiological and/or intensive care treatment

Exclusion Criteria:

• minority

• absence of written informed consent in the case of non-acute life-threatening disease

• persons who have a dependency or employment relationship with the sponsor or investigator

• persons who are sheltered in an institution upon court or administrative order

Related Conditions & MeSH terms

• Infection
• Intensive Care Patients

Intervention

Other:
• Telemedical support
Participating sites will be advised by telemedicine support.

Locations

Country	Name	City	State
Germany	University Hospital RWTH Aachen	Aachen	NRW
Germany	University Hospital Münster	Münster

Sponsors (1)

Lead Sponsor	Collaborator
RWTH Aachen University

Country where clinical trial is conducted

Germany, 

References & Publications (3)

Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K, Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007 Apr;33(4):606-18. Epub 2007 Feb 24. — View Citation

Laxminarayan R, Bhutta Z, Duse A, Jenkins P, O'Brien T, Okeke IN, Pablo-Mendez A, Klugman KP. Drug Resistance. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease Control Priorities in Developing Countries. 2nd edition. Washington (DC): World Bank; 2006. Chapter 55. — View Citation

Reinhart K, Brunkhorst FM, Bone HG, Bardutzky J, Dempfle CE, Forst H, Gastmeier P, Gerlach H, Gründling M, John S, Kern W, Kreymann G, Krüger W, Kujath P, Marggraf G, Martin J, Mayer K, Meier-Hellmann A, Oppert M, Putensen C, Quintel M, Ragaller M, Rossaint R, Seifert H, Spies C, Stüber F, Weiler N, Weimann A, Werdan K, Welte T; German Sepsis Society; German Interdisciplinary Association of Intensive Care and Emergency Medicine. Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)). Ger Med Sci. 2010 Jun 28;8:Doc14. doi: 10.3205/000103. English, German. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement of treatment quality	The level of implementation of the 10 recommendations of the German Society of Infectious Diseases (Deutsche Gesellschaft für Infektiologie, DGI) within the framework of the Initiative "Decide wisely" ("Klug entscheiden").	through study completion, an average of 30 days up to a maximum of 1 year
Secondary	Rate of sepsis diagnosis	Rate of sepsis diagnosis	through study completion, an average of 30 days up to a maximum of 1 year
Secondary	Rate of ARDS Diagnosis	Rate of ARDS Diagnosis	through study completion, an average of 30 days up to a maximum of 1 year
Secondary	Sepsis therapy in compliance with guidelines	Sepsis therapy in compliance with guidelines through for instance timely administration of antibiotics within 3 h and reduction of sepsis mortality.	through study completion, an average of 30 days up to a maximum of 1 year
Secondary	Rate of ARDS therapy according to guidelines	Measured against the evident ventilation targets, Ventilation with low ventilation volumes and low peak pressures: with controlled ventilation: Breath volume of 6 ml/kg calculated Body ideal weight, PEEP setting in proportion with the necessary FiO2, plateau pressure < 30 cm H2O	through study completion, an average of 30 days up to a maximum of 1 year
Secondary	Rate of inadequate antibiotic therapies	Measured by the Percentage of postoperatively continued perioperative Antibiotic prophylaxis	through study completion, an average of 30 days up to a maximum of 1 year
Secondary	Rate of patients with dialysis	Rate of patients with dialysis requiring Kidney insufficiency in discharge from the Intensive care	At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
Secondary	Rate of transfer transport	Rate of transfer transport	At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
Secondary	Health-related quality of life (SF36-Questionnaire)	Clinical studies 36-item Medical Outcomes Study Short-Form General Health Survey An instrument used to assess multidimensional health-related QOL, which measures 8 health related parameters: physical function, social function, physical role, emotional role, mental health, energy, pain, general health perceptions; each parameter is scored from 0 to 100 Managed care 36-Item Short-Form Functional and Perceived Health Status Survey A questionnaire which measures health status; the SF-36 also includes a list of 18 self-reported chronic conditions	At discharge from Intensive Care Unit (through study completion; an average of 30 days up to a maximum of 1 year), through study completion, an average of 12 months and 24 months after discharge of ICU
Secondary	Rate of non-diagnosed sepsis	Defined as no filled out sepsis bundle despite presence of sepsis symptoms	through study completion, an average of 30 days up to a maximum of 1 year
Secondary	Sepsis mortality rate	Sepsis mortality rate	through study completion, an average of 30 days up to a maximum of 1 year
Secondary	Hospital mortality rate	Hospital mortality rate	through study completion, an average of 30 days up to a maximum of 1 year
Secondary	Length of stay in intensive care unit	Length of stay in intensive care unit measured in hours	At discharge from Intensive Care Unit (study completion); after an average of 30 days up to a maximum of 1 year
Secondary	Hospital stay	Hospital stay measured in days	At discharge from Hospital; after an average of 30 days up to a maximum of 1 year

External Links

•   Jung, N. Klug entscheiden: . . . in der Infektiologie. Dtsch Arztebl 2016; 113(13): A-608 / B-514 / C-510